Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.70
MRK's Cash to Debt is ranked higher than
56% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. MRK: 0.70 )
MRK' s 10-Year Cash to Debt Range
Min: 0.37   Max: 1.93
Current: 0.7

0.37
1.93
Equity to Asset 0.47
MRK's Equity to Asset is ranked higher than
53% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. MRK: 0.47 )
MRK' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.53
Current: 0.47

0.37
0.53
Interest Coverage 7.94
MRK's Interest Coverage is ranked higher than
52% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.51 vs. MRK: 7.94 )
MRK' s 10-Year Interest Coverage Range
Min: 3.31   Max: 44.62
Current: 7.94

3.31
44.62
F-Score: 5
Z-Score: 3.05
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.44
MRK's Operating margin (%) is ranked higher than
82% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. MRK: 14.44 )
MRK' s 10-Year Operating margin (%) Range
Min: 5.15   Max: 43.77
Current: 14.44

5.15
43.77
Net-margin (%) 10.00
MRK's Net-margin (%) is ranked higher than
78% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. MRK: 10.00 )
MRK' s 10-Year Net-margin (%) Range
Min: 1.87   Max: 47.03
Current: 10

1.87
47.03
ROE (%) 8.85
MRK's ROE (%) is ranked higher than
78% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. MRK: 8.85 )
MRK' s 10-Year ROE (%) Range
Min: 1.58   Max: 45.99
Current: 8.85

1.58
45.99
ROA (%) 4.17
MRK's ROA (%) is ranked higher than
72% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. MRK: 4.17 )
MRK' s 10-Year ROA (%) Range
Min: 0.81   Max: 17.93
Current: 4.17

0.81
17.93
ROC (Joel Greenblatt) (%) 32.08
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. MRK: 32.08 )
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.45   Max: 82.93
Current: 32.08

10.45
82.93
Revenue Growth (%) -0.10
MRK's Revenue Growth (%) is ranked higher than
59% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. MRK: -0.10 )
MRK' s 10-Year Revenue Growth (%) Range
Min: -16.5   Max: 21.4
Current: -0.1

-16.5
21.4
EBITDA Growth (%) 12.60
MRK's EBITDA Growth (%) is ranked higher than
78% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. MRK: 12.60 )
MRK' s 10-Year EBITDA Growth (%) Range
Min: -17.6   Max: 44.7
Current: 12.6

-17.6
44.7
EPS Growth (%) 73.80
MRK's EPS Growth (%) is ranked higher than
97% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. MRK: 73.80 )
MRK' s 10-Year EPS Growth (%) Range
Min: -42.7   Max: 73.8
Current: 73.8

-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MRK Guru Trades in Q2 2013

Mark Hillman 17,807 sh (New)
Caxton Associates 5,000 sh (New)
George Soros 250,000 sh (New)
James Barrow 29,318,754 sh (+134.86%)
Jeremy Grantham 12,948,128 sh (+63.6%)
Paul Tudor Jones 458,100 sh (+60.57%)
Prem Watsa 12,000 sh (+50%)
Jean-Marie Eveillard 2,250,286 sh (+46.32%)
Charles Brandes 2,703,540 sh (+43.39%)
Ken Fisher 1,150,694 sh (+18.41%)
Murray Stahl 48,371 sh (+11.02%)
Irving Kahn 1,215,659 sh (+4.38%)
John Buckingham 32,599 sh (+1.52%)
Manning & Napier Advisors, Inc 419,693 sh (+1.02%)
Bill Frels 136,288 sh (+0.37%)
Brian Rogers 6,625,700 sh (unchged)
Louis Moore Bacon 2,078,000 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Vanguard Health Care Fund 35,919,648 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
John Hussman 2,625 sh (unchged)
Richard Snow 5,385 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
Diamond Hill Capital Sold Out
Dodge & Cox 50,697,146 sh (-1.11%)
Jeff Auxier 171,149 sh (-1.99%)
RS Investment Management 1,595,775 sh (-5.72%)
Tom Russo 5,736 sh (-8.02%)
Mario Gabelli 190,063 sh (-13.91%)
NWQ Managers 130,566 sh (-21.76%)
HOTCHKIS & WILEY 1,028,832 sh (-38.73%)
Joel Greenblatt 23,739 sh (-44.15%)
Pioneer Investments 2,440,016 sh (-48.75%)
Steven Cohen 57,569 sh (-56.67%)
Leon Cooperman 203,200 sh (-89.42%)
» More
Q3 2013

MRK Guru Trades in Q3 2013

Signature Select Canadian Fund 291,200 sh (New)
Jim Simons 252,300 sh (New)
Mario Gabelli 195,676 sh (+2.95%)
HOTCHKIS & WILEY 1,059,010 sh (+2.93%)
Jeremy Grantham 13,291,108 sh (+2.65%)
John Buckingham 33,169 sh (+1.75%)
James Barrow 29,641,593 sh (+1.1%)
Irving Kahn 1,228,533 sh (+1.06%)
Manning & Napier Advisors, Inc 422,047 sh (+0.56%)
RS Investment Management 1,601,873 sh (+0.38%)
Louis Moore Bacon 1,228,000 sh (unchged)
Vanguard Health Care Fund 35,919,648 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Tom Russo 5,736 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
Leon Cooperman 203,200 sh (unchged)
Mark Hillman 17,807 sh (unchged)
Richard Snow 5,385 sh (unchged)
John Hussman 2,625 sh (unchged)
George Soros Sold Out
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Charles Brandes 2,702,972 sh (-0.02%)
Jeff Auxier 171,049 sh (-0.06%)
Murray Stahl 48,121 sh (-0.52%)
Dodge & Cox 50,137,596 sh (-1.1%)
Pioneer Investments 2,407,299 sh (-1.34%)
NWQ Managers 125,255 sh (-4.07%)
Ken Fisher 1,099,750 sh (-4.43%)
Bill Frels 113,404 sh (-16.79%)
Steven Cohen 41,275 sh (-28.3%)
Jean-Marie Eveillard 1,134,041 sh (-49.6%)
» More
Q4 2013

MRK Guru Trades in Q4 2013

Ruane Cunniff 4,075 sh (New)
George Soros 150,000 sh (New)
Louis Moore Bacon 10,000 sh (New)
Jim Simons 2,018,534 sh (+700.05%)
Irving Kahn 2,525,376 sh (+105.56%)
Bill Frels 130,654 sh (+15.21%)
Ken Fisher 1,197,965 sh (+8.93%)
John Buckingham 34,302 sh (+3.42%)
RS Investment Management 1,633,719 sh (+1.99%)
Vanguard Health Care Fund 36,561,348 sh (+1.79%)
Richard Snow 5,410 sh (+0.46%)
Bill Nygren 1,587,000 sh (unchged)
Mario Gabelli 195,671 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Mark Hillman 17,807 sh (unchged)
George Soros 129,300 sh (unchged)
John Hussman 2,625 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Louis Moore Bacon 500,000 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Murray Stahl 48,071 sh (-0.1%)
Jeff Auxier 170,849 sh (-0.12%)
James Barrow 29,423,811 sh (-0.73%)
NWQ Managers 123,726 sh (-1.22%)
Dodge & Cox 48,798,496 sh (-2.67%)
Manning & Napier Advisors, Inc 409,182 sh (-3.05%)
HOTCHKIS & WILEY 1,018,710 sh (-3.81%)
Pioneer Investments 2,211,185 sh (-8.15%)
Charles Brandes 2,476,201 sh (-8.39%)
Tom Russo 4,536 sh (-20.92%)
Jeremy Grantham 9,665,336 sh (-27.28%)
Jean-Marie Eveillard 14,050 sh (-98.76%)
» More
Q1 2014

MRK Guru Trades in Q1 2014

Brian Rogers 6,625,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-12-31 Reduce -98.76%0.16%$45.09 - $50.18 $ 56.4718%14050
Leon Cooperman 2013-12-31 Sold Out 0.15%$45.09 - $50.18 $ 56.4718%0
Charles Brandes 2013-12-31 Reduce -8.39%0.14%$45.09 - $50.18 $ 56.4718%2476201
George Soros 2013-12-31 New Buy0.06%$45.09 - $50.18 $ 56.4718%150000
Ruane Cunniff 2013-12-31 New Buy$45.09 - $50.18 $ 56.4718%4075
Jean-Marie Eveillard 2013-09-30 Reduce -49.6%0.16%$46.55 - $48.58 $ 56.4718%1134041
George Soros 2013-09-30 Sold Out 0.13%$46.55 - $48.58 $ 56.4718%0
Joel Greenblatt 2013-09-30 Sold Out 0.05%$46.55 - $48.58 $ 56.4718%0
James Barrow 2013-06-30 Add 134.86%1.32%$44.35 - $49.44 $ 56.4721%29318754
Leon Cooperman 2013-06-30 Reduce -89.42%1.16%$44.35 - $49.44 $ 56.4721%203200
Charles Brandes 2013-06-30 Add 43.39%0.48%$44.35 - $49.44 $ 56.4721%2703540
George Soros 2013-06-30 New Buy0.13%$44.35 - $49.44 $ 56.4721%250000
Jean-Marie Eveillard 2013-06-30 Add 46.32%0.1%$44.35 - $49.44 $ 56.4721%2250286
Joel Greenblatt 2013-06-30 Reduce -44.15%0.04%$44.35 - $49.44 $ 56.4721%23739
Ray Dalio 2013-06-30 Sold Out 0.04%$44.35 - $49.44 $ 56.4721%0
Prem Watsa 2013-06-30 Add 50%0.01%$44.35 - $49.44 $ 56.4721%12000
James Barrow 2013-03-31 Add 38917.3%0.99%$40.85 - $45.04 $ 56.4732%12483576
Leon Cooperman 2013-03-31 Add 225.64%0.9%$40.85 - $45.04 $ 56.4732%1921300
Jean-Marie Eveillard 2013-03-31 Add 10846%0.23%$40.85 - $45.04 $ 56.4732%1537919
Joel Greenblatt 2013-03-31 Reduce -41.96%0.07%$40.85 - $45.04 $ 56.4732%42504
Ray Dalio 2013-03-31 Add 117.35%0.02%$40.85 - $45.04 $ 56.4732%95941
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

Bill Nygren Comments on Merck
We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value. Read more...
Vanguard Health Care Fund’s Top Five
Over the duration of the fourth quarter the Vanguard Health Care Fund purchased added four new stocks to its holdings. The fund now holds on to 93 stocks valued at $32.35 billion. The following companies are Vanguard's top five portfolio holdings. Read more...
Merck and Seadrill Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized two companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Diamond Hill Capital Growing - Six Sells
The updated portfolio of Diamond Hill Capital Management lists 15 stocks, 19 of them new, a total value at $9.28 billion, and a quarter-over-quarter turnover of 6%. The portfolio is currently weighted with top three sectors: financial services at 26.9%, technology at 14% and consumer defensive at 13.5%. Read more...
Prem Watsa's 4 Second Quarter Increases
The founder of Fairfax Financial Prem Watsa, oftentimes called the “Warren Buffett of Canada,” maintained a rather quiet second quarter, posting three small new buys. Over the past quarter, Prem Watsa increased his positions in four companies. Read more...
Irving Kahn Increases Four
Not many investors can claim 84 years of experience on their vitae. Born in 1905, America’s oldest value investor Irving Kahn, age 107, grew up in an era when 'news boys' delivered the newspaper and long before anyone could envision that news would someday be delivered digitally. Read more...
GuruFocus Names Ten Dividend Growers: July 22 to 26
During the past week, GuruFocus recognized 10 companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Dodge & Cox - Five Years of Pure Gains with Fantastic Five Holdings
Boston-based Dodge & Cox Funds, is one of the largest among all mutual fund, hedge fund and investment company Gurus, and is led by Dodge & Cox vice presidents Kevin Johnson and John Iannuccillo. The firm seeks long-term growth of principal and income with a secondary objective of achieving a reasonable current income. Lasteupdated by GuruFocus on June 7, 2013, the Dodge & Cox portfolio lists 163 stocks, two of them new, and a total value of $81.38 billion. Read more...
McDonald's and Four Others Named Dividend Growers Last Week
During the past week GuruFocus recognized five companies as dividend growers. In order to be considered for this list, the company had to: Read more...
Leon Cooperman's First Quarter Increases
Leon Cooperman’s current portfolio contains 81 stocks valued at over $6.5 billion. Leon Cooperman increased his holdings in 31 stocks in the most recent quarter; the following five companies represent Cooperman’s five largest increases of the quarter. Newcastle Investment Corporation (NCT) Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.60
MRK's P/E(ttm) is ranked higher than
54% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. MRK: 38.60 )
MRK' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 139.89
Current: 38.6

6.67
139.89
P/B 3.30
MRK's P/B is ranked higher than
58% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. MRK: 3.30 )
MRK' s 10-Year P/B Range
Min: 1.72   Max: 7.78
Current: 3.3

1.72
7.78
P/S 3.80
MRK's P/S is ranked lower than
56% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. MRK: 3.80 )
MRK' s 10-Year P/S Range
Min: 2.01   Max: 5.97
Current: 3.8

2.01
5.97
PFCF 16.80
MRK's PFCF is ranked higher than
81% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.79 vs. MRK: 16.80 )
MRK' s 10-Year PFCF Range
Min: 7.8   Max: 86.81
Current: 16.8

7.8
86.81
EV-to-EBIT 28.60
MRK's EV-to-EBIT is ranked higher than
52% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. MRK: 28.60 )
MRK' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 102.1
Current: 28.6

7.9
102.1
PEG 1.80
MRK's PEG is ranked higher than
75% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. MRK: 1.80 )
MRK' s 10-Year PEG Range
Min: 0.54   Max: 72.61
Current: 1.8

0.54
72.61
Shiller P/E 21.40
MRK's Shiller P/E is ranked higher than
71% of the 363 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. MRK: 21.40 )
MRK' s 10-Year Shiller P/E Range
Min: 8.31   Max: 22.81
Current: 21.4

8.31
22.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.10
MRK's Dividend Yield is ranked higher than
86% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. MRK: 3.10 )
MRK' s 10-Year Dividend Yield Range
Min: 2.42   Max: 6.68
Current: 3.1

2.42
6.68
Dividend Payout 1.18
MRK's Dividend Payout is ranked lower than
70% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. MRK: 1.18 )
MRK' s 10-Year Dividend Payout Range
Min: -1.46   Max: 5.43
Current: 1.18

-1.46
5.43
Dividend growth (3y) 4.40
MRK's Dividend growth (3y) is ranked higher than
77% of the 235 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. MRK: 4.40 )
MRK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14.8
Current: 4.4

0
14.8
Yield on cost (5-Year) 3.72
MRK's Yield on cost (5-Year) is ranked higher than
84% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. MRK: 3.72 )
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 2.9   Max: 8.01
Current: 3.72

2.9
8.01
Share Buyback Rate 1.30
MRK's Share Buyback Rate is ranked higher than
91% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. MRK: 1.30 )
MRK' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -13
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.10
MRK's Price/Tangible Book is ranked lower than
77% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. MRK: 12.10 )
MRK' s 10-Year Price/Tangible Book Range
Min: 3.83   Max: 43.95
Current: 12.1

3.83
43.95
Price/DCF (Projected) 1.50
MRK's Price/DCF (Projected) is ranked higher than
75% of the 349 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. MRK: 1.50 )
MRK' s 10-Year Price/DCF (Projected) Range
Min: 0.85   Max: 3.04
Current: 1.5

0.85
3.04
Price/Median PS Value 1.20
MRK's Price/Median PS Value is ranked higher than
52% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. MRK: 1.20 )
MRK' s 10-Year Price/Median PS Value Range
Min: 0.78   Max: 2.02
Current: 1.2

0.78
2.02
Price/Graham Number 4.40
MRK's Price/Graham Number is ranked lower than
66% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. MRK: 4.40 )
MRK' s 10-Year Price/Graham Number Range
Min: 1.17   Max: 14.83
Current: 4.4

1.17
14.83
Earnings Yield (Greenblatt) 3.50
MRK's Earnings Yield (Greenblatt) is ranked higher than
60% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. MRK: 3.50 )
MRK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 12.6
Current: 3.5

1
12.6
Forward Rate of Return (Yacktman) -0.43
MRK's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. MRK: -0.43 )
MRK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.6   Max: 22.1
Current: -0.43

-6.6
22.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:MRK.France, 6MK.Germany
Merck & Co Inc is a New Jersey corporation. The Company is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide